发明名称 |
WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE |
摘要 |
A compound represented by the formula (1):;;wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2):;;wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like. |
申请公布号 |
US2015238587(A1) |
申请公布日期 |
2015.08.27 |
申请号 |
US201514706772 |
申请日期 |
2015.05.07 |
申请人 |
Sumitomo Dainippon Pharma Co., Ltd. ;International Institute of Cancer Immunology, Inc. |
发明人 |
LI Chiang Jia;Ban Hitoshi;Nishio Yukihiro;Goto Masashi;Nishihara Toshio;Takanashi Yosuke |
分类号 |
A61K39/00;A61K47/48 |
主分类号 |
A61K39/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating cancer, comprising:
administering a therapeutically effective amount of a pharmaceutical composition to a WT1 positive cancer patient in need thereof, the pharmaceutical composition comprising
a compound represented by formula (1): or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier,wherein Xa and Ya are each a single bond,cancer antigen peptide A is a peptide consisting of an amino acid sequence selected from the group consisting of:RMFPNAPYL,(SEQ ID NO: 2)ALLPAVPSL,(SEQ ID NO: 5)SLGEQQYSV(SEQ ID NO: 6)andRVPGVAPTL,(SEQ ID NO: 7)an amino group of an N-terminal amino acid of the cancer antigen peptide A binds to Ya in the formula (1), a carbonyl group of a C-terminal amino acid of the cancer antigen peptide A binds to a hydroxyl group in the formula (1),R1 is a cancer antigen peptide C,the cancer antigen peptide C has a sequence different from a sequence of the cancer antigen peptide A, which is a peptide consisting of an amino acid sequence selected from the group consisting of:CMTWNQMNL(SEQ ID NO: 3)andCYTWNQMNL,(SEQ ID NO: 4)and a thioether group of the cysteine residue of the cancer antigen peptide C is bonded to the thioether group in the formula (1). |
地址 |
Osaka-shi JP |